Molecular Biotechnology

Validation of meprin α as antimigratory target in cancer

Project in cooperation with Protein and Drug Biochemistry Unit as well as Astacin Proteases Unit

Characterization of HERV envelope proteins with the aim of developing therapeutic antibodies for HERV-associated autoimmune and tumor diseases

In cooperation with: University Hospital and Polyclinic for Pediatrics I and University Hospital and Polyclinic for Neurology, University Hospital of the Martin Luther University Halle-Wittenberg, Germany

Human endogenous retroviruses (HERVs) and, more specifically, their envelope proteins are suspected of transporting diseases such as multiple sclerosis, rheumatism and tumor diseases. However, the actual function of these specific factors remains to be seen. Cellular damage and the misdirected stimulation of the immune system caused by HERV are assumed to be disease mechanisms. A joint research project between the Fraunhofer Institute for Cell Therapy and Immunology IZI and Halle University Hospital is expected to deliver new insights based on the characterization of HERV envelope proteins. The aim is to develop therapeutic antibodies for HERV-associated autoimmune and tumor diseases.

As part of the research project HERV envelope proteins will be produced using biotechnology and their biological activity will be characterized. These proteins will then also serve as antigens for generating both polyclonal and monoclonal antibodies. Finally, a suitable antibody is to be humanized, enabling it to be utilized in the human organism and in the development of therapies. The project is expected to pave the way for new therapeutic procedures to treat autoimmune and tumor diseases.

The project is being funded by the European Regional Development Fund (ERDF) and the State of Saxony-Anhalt. The project forms part of the “Saxony-Anhalt SCIENCE – FOCUS” program, through which the State of Saxony-Anhalt supports specialist research activities and innovative research projects in the field of science.

Biomarkers to predict vascular reocclusion following surgery

Arteriosclerotic changes in the body’s vessels are the primary cause of poor tissue perfusion. Depending on the perfusion area in question, this can lead to heart attacks and strokes. If, however, the muscles are not supplied with enough oxygen, many patients also experience impaired mobility, for instance due to pain in their legs. In advanced stages, the narrowed segment tends to either be circumvented by means of a bypass or the vessel is enlarged in the catheter laboratory using a balloon. For a high number of patients, however, this intervention is immediately followed by the treated vessel occluding once again, which in turn results in symptoms reemerging. An easily accessible biomarker capable of indicating respective negative processes at an early stage is therefore of great medical interest. The goal would be to more closely examine relevant high-risk patients with a view to intervening earlier and thus improving therapy results.

Researchers at Fraunhofer IZI have already identified a promising biomarker in previous studies – an enzyme (glutaminyl cyclase) whose activity is able to give a prognosis as to the healing process of the treated blood vessel. But these previous studies were initially only based on a small patient population. This biomarker can now be validated using a larger group of patients, graded according to concomitant diseases emerging in parallel such as type II diabetes mellitus or hyperlipidemia.

The Clinic for Vascular Surgery at the St. Elisabeth and St. Barbara Hospital in Halle (Saale), Germany, is an important partner here. Blood samples will be taken from patients at regular intervals before the operation and up to one year afterwards. These samples will then be sent to the Fraunhofer Institute for examination, as part of which a biochemical analysis of enzyme activity will be conducted in what will, to begin with, still be a relatively complex laboratory process. At the same time a simplified immunological test based on the amount of enzymes will be developed. A user-friendly and cost-efficient test would contribute to increased patient safety and make for a more targeted therapy for high-risk patients.

EFRE

Determination of pharmacokinetic parameters of small molecules

A comprehensive characterization of physico-chemical, cell-biological and pharmacokinetic properties of small molecules are prerequisite for their preclinical development. This process is required for the application of efficacious, safe and well-tolerated molecules in human subjects later during clinical development. Important steps during preclinics are investigations on liberation, absorption, distribution, metabolism and excretion (L-ADME parameters) in animal models. Here, information on exposure, bioavailability and terminal half-life will be collected. These data serve as decision points for selecting preclinical candidates or are used for optimization, e.g. bioavailability of an already selected candidate, by formulation development. The Department of Drug Design and Target Validation at Fraunhofer IZI develops new molecular therapies for neurodegenerative and inflammatory disorders. The department’s strategy includes identifying novel drug target and testing novel therapies. For characterizing new small molecule classes, a catheter-based rat model for analyzing pharmacokinetics of such compounds has been established by the Molecular Biotechnology unit. The model is comprised of surgical application of a catheter in the jugular vein (V. jugularis) and in the carotid artery (A. carotis communis), respectively. Using this method, it is possible to obtain complete compound profiles from a single animal, which avoids inter-individual variations, e.g. when using mice. In addition, a close collaboration with the Drug Design and Analytical Chemistry unit enables rapid determination of compounds concentrations in blood samples by LC-MS. The applied method is being used successfully within the Department of Drug Design and Target Validation, e.g. for own projects, such as the development of novel inhibitors for alternative beta-secretases or the development of novel inhibitors for the treatment of periodontitis. It is also requested and used by partners from industry and academia.

Pathological role of superantigens derived from expression of human endogenous retroviruses

Multiple Sclerosis (MS) is a progressive and chronic inflammatory disorder of the central nervous system. MS is characterized by a pathological demyelination of axons. Depending on the site of inflammation symptoms vary greatly and include paralysis or numbness of extremities, impaired vision and speech, dizziness, cognitive impairment, and fatigue. An underlying cause for the development of MS has not been identified so far. A widely accepted theory of MS pathology focusses on auto-reactive T-cells acting against axonal myelin. This simplistic view is challenged by a number of clinical observations arguing against a sole autoimmunological process.

First, newly emerging MS lesions are devoid of immune cells and second, MRI imaging suggests alterations in affected areas before the appearance of signs of inflammation. Furthermore, relapses during disease progression do not correlate with the disability patients face in the later stages of MS and standard therapy using immune modulatory and/or immune suppressive drugs has no influence on primary or secondary progredient forms of MS. Consequently, MS consists of 2 arms, 1) an inflammatory part (relapses) and 2) a slowly progressive neurodegenerative part.

The less understood 2nd arm might be correlated with the expression of human endogenous retroviruses (HERVs). HERVs are remnants of an ancient retroviral infection integrating viral DNA into the human genome. A number of HERVs still possess open reading frames, e.g. coding for the former viral envelope protein. These proteins could show superantigenic properties.

Therefore, the project focusses on the immunological properties of HERV-derived viral envelope proteins and the development of humanized monoclonal antibodies as alternative therapy for the treatment of MS.

Novel humanized animal models for studying the pathogenesis of Alzheimer’s disease

Alzheimer’s disease (AD) is characterized by a progressive loss of neurons and is accompanied by an impairment of learning and memory in elderly individuals. Besides major efforts in academic and industrial research, modeling the course of the disease in animals is challenging. A number of established animal models, especially mouse models of AD usually enable investigations only on certain pathological aspects. This is mainly attributed to the overexpression of Alzheimer-related genes in those models frequently including rare mutations devoid in patients with sporadic AD. We have selected 4 key proteins responsible for the development of AD and replaced them in mice by their human counterparts under control of the natural murine promoters. Fully humanization at these AD-specific loci by crossbreeding builds a platform to test new drugs against Alzheimer’s disease.

Rabbit model of in-stent restenosis for drug development

© Fraunhofer IZI

Coronary arteries narrowed by atherosclerotic changes are the underlying cause of angina pectoris and myocardial infarction. To re-open an occluded vessel, percutaneous transluminal angioplasty (PTA) with and without stent application is performed. Frequently, the operated vessel segment is re-occluded by hyperproliferation of smooth muscle cells in combination with invasion of monocytes forming a neointima. The process is called in-stent restenosis (ISR) if occurring after stent application.

The Molecular Biotechnology Unit has an established in vivo model of ISR available. Stent application in atherosclerotic New Zealand white rabbits is a powerful tool to investigate novel drug candidates, biomaterials and medicinal products.

Completed projects

  • Viromer carrier systems for the genebased treatment of inflammatory diseases
EFRE